Date | Price Target | Rating | Analyst |
---|---|---|---|
8/22/2024 | $16.00 | Buy | Rodman & Renshaw |
3/7/2024 | $5.00 | Hold → Buy | The Benchmark Company |
11/20/2023 | Underweight | JP Morgan | |
8/29/2023 | Buy → Hold | The Benchmark Company | |
4/10/2023 | $22.00 | Hold → Buy | The Benchmark Company |
3/17/2023 | $23.00 → $9.00 | Neutral → Underweight | JP Morgan |
11/10/2022 | Buy → Hold | The Benchmark Company | |
4/29/2022 | Overweight → Neutral | Cantor Fitzgerald |
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced the shelf-life extension for NARCAN® Nasal Spray from three years (36 months) to four years (48 months) to all newly manufactured product. The update makes NARCAN® Nasal Spray the only 4 mg, intranasal naloxone spray in Canada with this extended expiration date. The Health Canada notification to extend NARCAN® Nasal Spray's shelf-life was completed on February 2, 2024.
American Express Company (NYSE:AXP) will release its second-quarter financial results, before the opening bell on Friday, July 19. Analysts expect the New York-based company to report quarterly earnings at $3.25 per share, up from $2.89 per share in the year-ago period. American Express will post revenue of $16.59 billion, compared to $15.05 billion a year earlier, according to data from Benzinga Pro. On July 16, Compass Point analyst David Rochester initiated coverage on American Express with a Neutral rating and announced a price target of $260. With the recent buzz around American Express, some investors may be eyeing potential gains from the company's dividends, too. As of now,
Johnson & Johnson (NYSE:JNJ) will release its second-quarter financial results, before the opening bell on Wednesday, July 17. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.70 per share, up from $2.56 per share in the year-ago period. Johnson & Johnson is expected to post revenue of $22.29 billion, compared to $25.53 billion a year earlier, according to data from Benzinga Pro. Emergent BioSolutions Inc (NYSE:EBS), through its subsidiary Emergent Manufacturing Operations Baltimore, recently reached a settlement with Janssen Pharmaceuticals, Inc., a branch of Johnson & Johnson, resolving disputes related to the manufacturing of Johnson & J
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00
The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00
JP Morgan resumed coverage of Emergent BioSolutions with a rating of Underweight
Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance rangeSecond Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) millionUpdates FY 2024 guidance GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the second quarter ended June 30, 2024. "In the first half of the year, we made great progress to stabilize our financial position by strategically divesting assets, resolving several legacy issues, and securing operational cash flow and working capital improvements," said Joe Papa, president and CEO at Emergent. "As a result, we ex
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of 2024, as well as full year guidance. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that
First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products," said Joe Papa, President and CEO at Emergent. "We also took significant actions to improve our debt position, reduce operating expenses and strengthen our financial flexibility. Emergent's transformation will not happen overnight. The actions we
GAITHERSBURG, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it entered into a new credit agreement on September 30, 2024 providing for an asset-based revolving loan facility (ABL) with the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent. The credit agreement provides for revolving loan commitments in an aggregate principal amount up to $100 million (availability is based on a borrowing base set forth therein) with a fixed maturity date of September 30, 2029, subject to early maturity triggers based on the maturity of its other material indebtedness. The new credit facility brings additional liquid
GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) ("Emergent") today announced that two contract options have been secured to procure additional treatment courses of TEMBEXA® (brincidofovir) to sustain the U.S. government's national preparedness posture against human smallpox. TEMBEXA® is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The order is valued at $67.4 million and executes procurement options CLIN0004A and CLIN0005A under Emergent's existing 10-year contract. "This announcement highlights the strength of the longstanding partnership between Emergent and the U.S. government to
GAITHERSBURG, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. This includes the previously disclosed U.S. government contract modification to procure ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live), as well as CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) contract options exercised in 2023 and 2024. To date in 2024, customer orders of nearly $210 million have been delivered for ACAM2000® and VIGIV. For the remainder of 2024 and into 2025, Emergent is confirmed to deliver an incremental
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. ("Bora", TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent's Contract Development and Manufacturing Organization (CDMO), has clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. Alongside the facility, approximately 350 curre
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)